ImmuCell Corporation (ICCC)
Automate Your Wheel Strategy on ICCC
With Tiblio's Option Bot, you can configure your own wheel strategy including ICCC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ICCC
- Rev/Share 900.4307
- Book/Share 3658.9526
- PB 0.0021
- Debt/Equity 0.2072
- CurrentRatio 4.1181
- ROIC 0.0124
- MktCap 61363946.0
- FreeCF/Share 138.5575
- PFCF 0.0493
- PE 0.0422
- Debt/Assets 0.1317
- DivYield 0
- ROE 0.1989
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 1
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) will be conducted virtually on Thursday, June 12, 2025, at 9:30 AM ET, as previously disclosed in its Proxy Statement that was filed with the Securities and Exchange Commission (“SEC”) on April 24, 2025.
Read More
ImmuCell Reports Y/Y Q1 Earnings Growth on Record Sales & Margin Gains
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
ICCC posts record Q1 sales, returns to earnings and expands margins y/y as First Defense demand grows and production issues subside.
Read More
ImmuCell Corporation (ICCC) Q1 2025 Earnings Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
ImmuCell Corporation (NASDAQ:ICCC ) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Company Participants Joe Diaz - Managing Partner, Lytham Partners, LLC Michael Brigham - President & Chief Executive Officer Tim Fiori - Chief Financial Officer Conference Call Participants George Melas - MKH Management Russ Tolander - Capital Alliance Operator Good morning and welcome to the ImmuCell Corporation Reports First Quarter Ended March 31st, 2025 Audited Financial Results Conference Call. All participants will be in listen-only mode.
Read More
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2025 after the market closes on Wednesday, May 14, 2025. The Company is planning to host a conference call the next morning, Thursday, May 15, 2025, at 9:00 AM ET to review the unaudited financial results.
Read More
ImmuCell Posts Y/Y Q4 Earnings Growth, Awaits FDA Approval for Re-Tain
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
ImmuCell posts 52% y/y sales growth in Q4. It improves margins and eyes FDA approval for Re-Tain to drive expansion.
Read More
ImmuCell Corporation (ICCC) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
ImmuCell Corporation (NASDAQ:ICCC ) Q4 2024 Earnings Conference Call February 26, 2025 9:00 AM ET Company Participants Joe Diaz - Managing Partner, Lytham Partners, LLC Michael Brigham - President and Chief Executive Officer Conference Call Participants George Melas-Kyriazi - MKH Management Operator Good morning, and welcome to ImmuCell Corporation Reports its Fourth Quarter and Year Ended December 31, 2024, Unaudited Financial Results Conference Call. All participants will be in listen-only mode.
Read More
About ImmuCell Corporation (ICCC)
- IPO Date 1987-05-05
- Website https://immucell.com
- Industry Biotechnology
- CEO Michael F. Brigham
- Employees 69